Dr Reddy's Laboratories, an integrated global pharmaceutical company, on February 17 announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Xeloda brand and generic had U.S. sales of approximately USD 90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.

Dr. Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Shares of the company declined Rs 84.05, or 1.79%, to trade at  Rs 4,611.95.  The total volume of shares traded  was  10,109 at the BSE (12.24 p.m., Wednesday).